CL2012001835A1 - Uso de una formulacion que comprende un agente viscogenico y moxifloxacina para preparar un medicamento util para tratar el oido medio. - Google Patents

Uso de una formulacion que comprende un agente viscogenico y moxifloxacina para preparar un medicamento util para tratar el oido medio.

Info

Publication number
CL2012001835A1
CL2012001835A1 CL2012001835A CL2012001835A CL2012001835A1 CL 2012001835 A1 CL2012001835 A1 CL 2012001835A1 CL 2012001835 A CL2012001835 A CL 2012001835A CL 2012001835 A CL2012001835 A CL 2012001835A CL 2012001835 A1 CL2012001835 A1 CL 2012001835A1
Authority
CL
Chile
Prior art keywords
moxifloxacin
formulation
middle ear
prepare
treating
Prior art date
Application number
CL2012001835A
Other languages
English (en)
Inventor
Roland J Sawchuk
Belinda W Y Cheung
Michael Wall
Original Assignee
Univ Minnesota
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44306169&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012001835(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Minnesota, Novartis Ag filed Critical Univ Minnesota
Publication of CL2012001835A1 publication Critical patent/CL2012001835A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Método de administración de moxifloxacina en el oído medio de un mamífero que comprende la aplicación de una formulación acuosa comprendiendo un agente viscogénico y moxifloxacina, la cual es fluida y tiene una viscosidad menor que los 100.000 CPS; y kit que comprende a la formulación e instrucciones para su aplicación.
CL2012001835A 2010-01-07 2012-07-06 Uso de una formulacion que comprende un agente viscogenico y moxifloxacina para preparar un medicamento util para tratar el oido medio. CL2012001835A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29301910P 2010-01-07 2010-01-07

Publications (1)

Publication Number Publication Date
CL2012001835A1 true CL2012001835A1 (es) 2013-03-22

Family

ID=44306169

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012001835A CL2012001835A1 (es) 2010-01-07 2012-07-06 Uso de una formulacion que comprende un agente viscogenico y moxifloxacina para preparar un medicamento util para tratar el oido medio.

Country Status (24)

Country Link
US (1) US20120289541A1 (es)
EP (2) EP3305280A1 (es)
JP (3) JP2013516485A (es)
KR (2) KR20180027611A (es)
CN (2) CN102791270A (es)
AU (1) AU2011204275B2 (es)
BR (1) BR112012016809A2 (es)
CA (1) CA2786525A1 (es)
CL (1) CL2012001835A1 (es)
CY (1) CY1119493T1 (es)
DK (1) DK2521547T3 (es)
ES (1) ES2644826T3 (es)
HR (1) HRP20171592T1 (es)
HU (1) HUE035586T2 (es)
LT (1) LT2521547T (es)
MX (1) MX337419B (es)
NO (1) NO2521547T3 (es)
PH (1) PH12012501371A1 (es)
PL (1) PL2521547T3 (es)
PT (1) PT2521547T (es)
RU (2) RU2016101214A (es)
SI (1) SI2521547T1 (es)
WO (1) WO2011085209A2 (es)
ZA (1) ZA201205965B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220431B2 (en) * 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
BR112014032568A2 (pt) * 2012-06-28 2017-06-27 The Administrators Of The Tulane Educational Fund composições seletivamente polimerizáveis e métodos de uso in vivo
CN103869033B (zh) * 2012-12-14 2016-10-05 南京长澳医药科技有限公司 一种液相色谱法分离测定盐酸莫西沙星及其杂质的方法
JP6255134B1 (ja) * 2016-11-02 2017-12-27 ヴェローチェ・バイオファーマ・エルエルシー 耳炎の治療のための組成物および方法
CA3084807A1 (en) * 2017-12-08 2019-06-13 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
CN108593696B (zh) * 2018-04-26 2020-11-03 南京明捷生物医药检测有限公司 一种利用定量核磁测定多肽中三氟乙酸残留的方法
CN117045593B (zh) * 2023-09-19 2024-05-28 上海市第六人民医院 一种用于慢性中耳炎治疗的抗菌温敏水凝胶及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6740664B2 (en) * 1998-09-30 2004-05-25 Alcon, Inc. Methods for treating otic and ophthalmic infections
AR020661A1 (es) * 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
JP3450805B2 (ja) * 2000-08-08 2003-09-29 わかもと製薬株式会社 水性医薬組成物
US7220431B2 (en) * 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
ZA200704775B (en) * 2004-12-10 2008-08-27 Alcon Inc Compositions for treatment of ear infections
WO2009142719A2 (en) * 2008-05-19 2009-11-26 Massachusetts Institute Of Technology Tympanic membrane permeating ear drops and uses thereof

Also Published As

Publication number Publication date
CY1119493T1 (el) 2018-03-07
PT2521547T (pt) 2017-11-17
JP2018076352A (ja) 2018-05-17
PL2521547T3 (pl) 2018-01-31
JP2016155808A (ja) 2016-09-01
KR20120114344A (ko) 2012-10-16
ES2644826T3 (es) 2017-11-30
EP2521547A2 (en) 2012-11-14
RU2576029C2 (ru) 2016-02-27
CA2786525A1 (en) 2011-07-14
RU2012133568A (ru) 2014-02-20
WO2011085209A2 (en) 2011-07-14
CN102791270A (zh) 2012-11-21
MX2012007928A (es) 2012-11-22
JP2013516485A (ja) 2013-05-13
KR20180027611A (ko) 2018-03-14
AU2011204275B2 (en) 2015-04-02
JP6267246B2 (ja) 2018-01-24
AU2011204275A1 (en) 2012-08-23
ZA201205965B (en) 2014-01-29
WO2011085209A3 (en) 2011-11-17
KR101835895B1 (ko) 2018-03-07
RU2016101214A (ru) 2018-11-21
EP3305280A1 (en) 2018-04-11
SI2521547T1 (en) 2018-02-28
PH12012501371A1 (en) 2012-10-22
MX337419B (es) 2016-03-03
NO2521547T3 (es) 2018-01-13
DK2521547T3 (da) 2017-11-20
HRP20171592T1 (hr) 2018-02-09
CN106309356A (zh) 2017-01-11
EP2521547A4 (en) 2014-03-26
LT2521547T (lt) 2017-12-11
BR112012016809A2 (pt) 2017-09-26
HUE035586T2 (en) 2018-05-28
US20120289541A1 (en) 2012-11-15
EP2521547B1 (en) 2017-08-16

Similar Documents

Publication Publication Date Title
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
AR068867A1 (es) Composiciones de fluido para tratamianto de pozos que incluyen una formulacion de percarbonato de liberacion retardada y metodos para usarlas
PE20150200A1 (es) Formulacion de anticuerpos
CL2015001984A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
CL2011001811A1 (es) Un metodo para tratar un paciente que ha sufrido un infarto agudo al miocardio que comprende el uso de un agente antifibrotico.
CR20150216A (es) Composiciones y métodos para tratar proteinopatías
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
PT2755473T (pt) Composições parasiticidas compreendendo um agente ativo de isoxazolina, métodos e suas utilizações
DOP2012000245A (es) Composiciones sólidas
MX2017001512A (es) Compuestos activos hacia bromodominios.
BR112013001027A2 (pt) agente de escoramento, e, métodos de formar um agente de escoramento para fraturar hidraulicamente uma formação subterrânea, e de fraturar hidraulicamente uma formação subterrânea
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
BR112012013883A2 (pt) método
CL2011002595A1 (es) Uso de una combinacion de un agente anticancerigeno y un antioxidante para tratar el cancer; y compicicion farmaceutica que comprende dicha combinacion.
CL2013000098A1 (es) Composicion farmaceutica que contienen una formulacion activada y potenciada de un anticuerpo para el receptor canabinoide humano; metodos de uso.
AR098688A1 (es) Métodos para minimizar el sobredesplazamiento de apuntalante en tratamientos de fracturas
MX2014015807A (es) Composiciones colorantes para cabello que comprenden 2-metoximetil-1,4-diaminobenceno y 2,6-diaminopiridina, metodos y estuches que comprenden las composiciones.
PE20200338A1 (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil
WO2014153009A3 (en) Thiosaccharide mucolytic agents
ECSP17057364A (es) Encapsulado de agentes activos de alta potencia
MX376628B (es) Composiciones para el cuidado bucal.
GT201600050A (es) Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso
MX2017009699A (es) Composicion de suspension oftalmica.
AR101236A1 (es) Composiciones para el cuidado oral
DOP2016000007A (es) Pirazolpiridinas sustituidas